๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 14 Shanghai 9 Guangzhou 7 Harbin 6 Hefei 4
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing14 Shanghai9 Guangzhou7 Harbin6 Hefei4
All 36 locations
Target enrolment
to

Trials with a site in Beijing

14 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors
NCT07480733Advanced Malignant Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
410
Beijing
2026-04-23
Recruiting
A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma
NCT07484724Advanced Esophageal Squamous Cell Carcinoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
280
Beijing
2026-04-13
Recruiting
JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.
NCT07284134Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
560
Hefei, Beijing, Fuzhou, Lanzhou, Wuwei, Guangzhou, Meizhou, Shantou
2025-12-24
Recruiting
JS207 Combination Therapy in Triple-negative Breast Cancer
NCT07045311Triple-negative Breast Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
80
Hefei, Beijing, Guangzhou, Baoding, Harbin, Zhangzhou, Wuhan, Nanjing
2025-09-17
Active, closed
JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma
NCT07081022B-cell Non-Hodgkin's Lymphoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
180
Beijing
2025-08-17
Recruiting
Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy
NCT06924606Advanced NSCLC
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
66
Beijing, Jilin City, Hunan, Sichuan, Chongqing, Guangdong, Heilongjiang, Anyang
2025-07-15
Recruiting
JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
NCT06954467Hepatocellular Carcinoma
DrugsJS007·JS207
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
72
Hefei, Beijing, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2025-05-29
Recruiting
A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer
NCT06885385Advanced Colorectal Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
60
Beijing, Shanghai
2025-04-23
Recruiting
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
NCT06095583Limited-stage Small Cell Lung Cancer (LS-SCLC)
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
756
Harbin, Changsha, Nanchang, Shenyang, Jinan, Anyang, Beijing, Changchun
2023-11-15
Active, closed
Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
NCT05618327Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
DrugJS203
Shanghai Junshi Bioscience Co., Ltd.
Phase 1
104
Beijing
2023-02-13
Recruiting
Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia
NCT05621070Primary Hypercholesterolaemia and Mixed Dyslipidemia
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
582
Beijing
2023-02-03
Active, closed
PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
NCT05180734Gastric or Esophagogastric Junction Adenocarcinoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
878
Bengbu, Chizhou, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Wuwei
2022-02-10
Rows per page Showing 1–14 of 14
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 14 of those studies with a site in Beijing that also match the filters currently applied.

How many clinical trials are recruiting in Beijing?

10 of the 14 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beijing), 14 studies
PhaseStudiesRecruitingShare
Phase 27650%
Phase 36442.9%
Phase 1107.1%

Most active sponsors

Lead sponsors with the most studies (Beijing)
Lead sponsorStudiesRecruiting
Shanghai Junshi Bioscience Co., Ltd.1410
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.